725
Views
6
CrossRef citations to date
0
Altmetric
Letter to the Editor

Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?

Pages 793-795 | Published online: 12 Aug 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Paolo Ricchi & Maria Marsella. (2015) Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes. Drug Design, Development and Therapy 9, pages 6475-6482.
Read now

Articles from other publishers (5)

George J. Kontoghiorghes. (2021) Differences between the European Union and United States of America in Drug Regulatory Affairs Affect Global Patient Safety Standards and Public Health Awareness: The Case of Deferasirox and Other Iron Chelating Drugs. Medicines 8:7, pages 36.
Crossref
Upendra Bulbake, Alka Singh, Abraham J. Domb & Wahid Khan. (2019) Therapeutic Macromolecular Iron Chelators. Current Medicinal Chemistry 26:2, pages 323-334.
Crossref
Christina N Kontoghiorghe & George J Kontoghiorghes. (2016) New developments and controversies in iron metabolism and iron chelation therapy. World Journal of Methodology 6:1, pages 1.
Crossref
Jasmine L Hamilton & Jayachandran N Kizhakkedathu. (2015) Polymeric nanocarriers for the treatment of systemic iron overload. Molecular and Cellular Therapies 3:1.
Crossref
Joshua P. Gray & Sidhartha D. Ray. 2015. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions 259 272 .